Policy and Medicine Compliance Update is our monthly compliance publication designed to help compliance professionals go in depth in issues and stay up to date on the latest trends. We encourage you to subscribe to our monthly publication Policy and Medicine Compliance Update.
For our first issue of 2022, we begin with an exploration of the paradoxically view of qui tam whistleblowers and the continuing skepticism of their motives for bringing False Claim Act (“FCA”) cases. Next, we provide an update on the proposed amendments to the involving labor market collusion and no-poach agreements. It seems this issue is making a resurgence under the Biden administration.
We also examine the recent decision by the Oklahoma Supreme Court overturning the verdict against J&J for opioid marketing. The case highlights the continuing struggle to hold manufacturers, distributors, and pharmacies responsible for their alleged role in creating the current epidemic. Finally, we also review California’s recent attempt to hold opioid manufacturers accountable that suffered a similar setback.
By Dr. Seth B. Whitelaw, Editor
Summary: Even with the current whistleblower protections, deciding whether to come forward is complex and challenging. Despite the demonstrable contributions whistleblowers make to combatting fraud and misconduct, skepticism about their motivations by Government regulators, attorneys, and compliance professionals...
News, Editor's Desk Pressure continues to mount on the Jewellers Association of Australia (JAA) concerning its relationship with jewellery industry suppliers and wholesalers. Last month, Jeweller r...